血清层粘连蛋白γ2单体作为肝细胞癌诊断与预测生物标志物
该研究探讨了层粘连蛋白γ2单体(LG2m)在肝细胞癌(HCC)诊断和预测中的价值。在细胞系和微阵列数据中,LG2m表达与预后差的分子亚类相关且不能被AFP识别。血清LG2m诊断HCC的敏感性和特异性分别为62.9%和70.5%( cutoff 30 pg/mL),高LG2m HCC预后差且易发生远处转移(cutoff 60 pg/mL)。在慢性丙型肝炎(CHC)患者中,LG2m升高与HCC高发生率相关,并在获得持续病毒学应答(SVR)的多中心前瞻性队列中得到验证(P < 0.0001)。
要点
- 血清LG2m诊断HCC的敏感性62.9%、特异性70.5%(cutoff 30 pg/mL)。
- LG2m-high HCC预后差,易发生远处转移(cutoff 60 pg/mL)。
- CHC患者即使获得SVR,LG2m升高仍与HCC高发生率相关(P < 0.0001)。
核心结论
- LG2m是转移性HCC的预测生物标志物,血清LG2m升高是获得SVR的CHC患者发生HCC的风险因素。
研究设计与样本
- 研究评估了HCC细胞系中LG2m表达,并利用14个细胞系和258例HCC微阵列数据进行分析。
- 血清LG2m在24名健康供者、133例慢性肝病患者和142例HCC患者中检测。
- 在兩個独立HCC队列(n=47和n=81)中评估LG2m升高的后果。
- 多中心前瞻性研究纳入399例获得SVR的CHC患者进行验证。
主要发现
- LG2m在AFP阴性、CD90阳性且高转移性的HCC细胞系中表达。
- LG2m基因特征与Hoshida S1/Boyault G3分子亚类相关,该亚类预后差且不能被AFP识别。
- 血清LG2m诊断HCC的敏感性和特异性分别为62.9%和70.5%(cutoff 30 pg/mL)。
- LG2m-high HCC(cutoff 60 pg/mL)预后差,后期发生远处器官转移。
- 在获得SVR的CHC患者中,血清LG2m升高与HCC高发生率相关(P < 0.0001)。
关键数值与推荐
- 血清LG2m诊断HCC的cutoff值为30 pg/mL,敏感性62.9%,特异性70.5%。
- 预测HCC预后和转移的LG2m cutoff值为60 pg/mL。
- 在获得SVR的CHC患者中,LG2m升高与HCC高发生率相关(P < 0.0001)。
临床怎么用
- 血清LG2m可作为HCC诊断的辅助生物标志物,尤其对AFP阴性患者。
- LG2m高水平提示HCC预后差和远处转移风险,需密切监测。
- CHC患者获得SVR后,若血清LG2m升高,应警惕HCC发生风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDS AND AIMS: Structural dynamics of basement membrane components are still to be elucidated in the process of hepatocarcinogenesis. We evaluated the characteristics of HCC expressing laminin γ2 monomer (LG2m), a basement membrane component not detected in normal tissues, for HCC diagnosis. We further determined whether elevated serum LG2m is a risk factor for HCC development in patients with chronic hepatitis C (CHC). APPROACH AND RESULTS: In HCC cell lines, LG2m was expressed in alpha-fetoprotein (AFP)-negative, CD90-positive cells characterized by highly metastatic natures. Using 14 cell lines and 258 HCC microarray data, we identified that LG2m gene signature was associated with Hoshida's S1/Boyault's G3 molecular subclasses with poor prognosis, which could not be recognized by AFP. Serum LG2m was assessed in 24 healthy donors, 133 chronic liver disease patients, and 142 HCC patients, and sensitivity and specificity of LG2m testing for HCC diagnosis were 62.9% and 70.5%, respectively (cutoff, 30 pg/mL). We evaluated the consequence of LG2m elevation in two independent HCC cohorts (n = 47 and n = 81), and LG2m-high HCC showed poor prognosis with later development of distant organ metastasis (cutoff, 60 pg/mL). LG2m was slightly elevated in a subset of CHC patients, and Kaplan-Meier analysis indicated a high incidence of HCC (n = 70). For validation, we enrolled 399 CHC patients with sustained virological response (SVR) as a multicenter, prospective study, and serum LG2m elevation correlated with a high incidence of HCC in the CHC patients with SVR (P < 0.0001). CONCLUSIONS: LG2m is a predictive biomarker for the development of metastatic HCC. Elevated serum LG2m is an HCC risk in CHC patients who have achieved SVR.
引用
- Yamashita T, Koshikawa N, Shimakami T, et al. Serum Laminin γ2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma. Hepatology. 2021. PMID: 33609304. doi:10.1002/hep.31758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。